COMPANY PROFILE

Morgenesis

Explore full profile

A subsidiary of Orgenesis, and it provides point-of-care services

Cazenovia, United StatesBiotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Total funding $10–50M Disclosed equity funding

At a glance

Status: Operational
Headquarters: Cazenovia, United States
Open positions: None listed
Dealroom signal: 23.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model: SaaS
Client focus: b2b

Founder mafia, market maps, research and news connected to this company by Dealroom

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GROWTH EQUITY VC✓Equity / VC	Dec 2022	$30M	$125M	Metalmark Capital	↗

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FIFibroBiologicsDeveloping therapies using fibroblasts, which are a type of cell that is found in connective tissue	Houston, United States	Operational	14	$103M	$253M
OBOcelot BioBiotech & Life Sciences	San Diego, United States	Operational
1T101 TherapeuticsDeveloping the first targeted glucocorticoid with all of the potency of steroids but none of the systemic toxicities	Tel Aviv-Yafo, Israel	Operational
CICianatxInnovative therapies for Diabetic Retinopathy, preventing vision loss and blindness with novel treatments	Annapolis, United States	Operational
APAculys PharmaCommitted to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease	Fujisawa, Japan	Acquired
BIBiofronteraSpecializing in dermatological products commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics	Woburn, United States	Operational
EBEucure BiopharmaInnovative immuno-oncology targeted antibodies advancing through clinical trials	Guangzhou, China	Operational
ETElastrin TherapeuticsReversing diseases by targeting damaged elastin fibers	Simpsonville, United States	Operational